Prof. Dr. Ralf Huss
BioM Biotech Cluster Development GmbH
Symposien
Saal: Terrassensaal A
Since the Nobel Prize honoured technology to produce monoclonal antibodies was invented in the 1970s, monoclonal antibodies have revolutionized medicine. And the evolution continues. Traditional monoclonal antibodies can now be modified to do their job in therapy even better. So called next generation antibody therapeutics include e. g. antibody–drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments and nanobodies. This symposium highlights some examples of promising candidates.
Prof. Dr. Ralf Huss
BioM Biotech Cluster Development GmbH
Dr. Jan Schmidt-Brand
Heidelberg Pharma AG
ATACs: A Unique New Mode of Action to Fight Cancer
Dr. Thorsten Schmidt
Sanofi-Aventis Deutschland GmbH
High Throughput and Computational Engineering Technologies for the Development of Multispecific Protein Therapeutics